Treprostinil sodium - Generic Drug Details

What are the generic drug sources for treprostinil sodium and what is the scope of freedom to operate?

Treprostinil sodium is the generic ingredient in one branded drug marketed by Liquidia Tech and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Treprostinil sodium has twelve patent family members in six countries.

There are six drug master file entries for treprostinil sodium. One supplier is listed for this compound.

Summary for treprostinil sodium

International Patents:	12
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	1
Clinical Trials:	19
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for treprostinil sodium
DailyMed Link:	treprostinil sodium at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for treprostinil sodium

Constraining patent/regulatory exclusivity:

NEW PRODUCT

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for treprostinil sodium

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AOP Orphan Pharmaceuticals AG	PHASE3
Eli Lilly and Company	Phase 1
Stanford University	Phase 2

See all treprostinil sodium clinical trials

Pharmacology for treprostinil sodium

Drug Class	Prostacycline Vasodilator
Physiological Effect	Vasodilation

Anatomical Therapeutic Chemical (ATC) Classes for treprostinil sodium

B01AC	Platelet aggregation inhibitors excl. heparin
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

US Patents and Regulatory Information for treprostinil sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-003	May 23, 2025		RX	Yes	Yes
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-003	May 23, 2025		RX	Yes	Yes
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005-002	May 23, 2025		RX	Yes	Yes

International Patents for treprostinil sodium

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017192993
European Patent Office	3452170	POUDRE SÈCHE DE TRÉPROSTINIL POUR LE TRAITEMENT DE L'HYPERTENSION PULMONAIRE (DRY POWDER TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION)
Australia	2017261317	Dry powder treprostinil for the treatment of pulmonary hypertension

Market Dynamics and Financial Trajectory of Treprostinil Sodium

Last updated: February 14, 2026

Overview Treprostinil sodium is a prostacyclin analog used primarily for the treatment of pulmonary arterial hypertension (PAH). Approved by the FDA in 2002, it is marketed as Remodulin in the United States and has multiple formulations, including intravenous, subcutaneous, inhaled, and oral. Its clinical profile and regulatory approvals influence market positioning and revenue streams.

Market Size and Growth Trends The global PAH treatment market is valued at approximately USD 4.8 billion in 2022, with a compound annual growth rate (CAGR) of around 6% projected through 2028. Treprostinil sodium comprises a significant share of this market, owing to its differentiated delivery methods.

• Key Figures:
  • 2022 global revenues: Estimated USD 600 million
  • Market share: Approximately 12-15%
  • Growth Drivers: Growing prevalence of PAH, increased detection, and expanded indications.

Regulatory Status and Market Penetration Treprostinil sodium has received approval in multiple regions:

• United States (FDA, 2002)
• European Union (EMA, 2004)
• Japan (PMDA, 2012)

It holds approval for patients with PAH WHO Group 1, particularly those with functional class II-IV symptoms.

• Oral Formulation: Approved by the FDA in 2021, expands market access, especially to outpatient settings.

Competitive Landscape The key competitors include:

• Epoprostenol (Flolan)
• Iloprost (Ventavis)
• Selexipag (Uptravi)
• Macitentan (Opsumit)

Treprostinil's multiple delivery options give it flexibility but face competition from oral agents like selexipag and macitentan, which are oral and have easier administration.

Financial Trajectory and Revenue Drivers

• Historical Revenue Trends: Revenues have oscillated due to changing formularies, generic entries, and advancements in alternative therapies.

• Revenue Forecasts:

  • Expected to reach USD 750-900 million globally by 2028, driven by oral formulation adoption.
  • Uncertain impact from generic competition in the future, with some markets experiencing patent exclusivities until 2030.

• Pricing Strategies:

  • Brand premiums attached to inhaled and IV formulations.
  • Price reductions expected for generic versions, potentially affecting profitability.

Key Market Factors

• R&D Investment: Focused on oral formulations and combination therapies.
• Market Access: Reimbursement policies vary, influencing revenue.
• Pipeline Developments: Drugs in clinical trials aim to expand treatment options or improve delivery methods, potentially challenging current market leaders.

Supply Chain and Manufacturing Manufacturing complexity, especially for injectable formulations, sustains high production costs. Supply chain disruptions may impact availability and, consequently, revenue streams.

---

Key Takeaways

• Treprostinil sodium commands a notable share of the PAH market, with revenues influenced by formulation preferences.
• The upcoming oral formulation is expected to significantly boost sales, especially in outpatient settings.
• Competition from oral agents and potential generics pose risks to future market share.
• Regulatory approvals across key regions facilitate global market penetration.
• Continued R&D and pipeline progress are crucial for maintaining growth.

---

Frequently Asked Questions

1. How does Treprostinil sodium compare to other PAH treatments in terms of efficacy?
It has demonstrated significant improvements in exercise capacity and symptom management. However, direct head-to-head trials are limited; clinicians often select among therapies based on patient needs and formulation availability.

2. What are the major patent and exclusivity considerations?
Patents on the injectable formulations extend into the late 2020s, while the oral formulations’ patents are expected to last until approximately 2030. Entry of generics could impact pricing and market share.

3. How does the mode of delivery influence market penetration?
Injectable and inhaled forms face barriers including administration complexity and patient preference. The oral formulation expands accessibility, thus potentially increasing revenue.

4. What are the primary factors affecting Treprostinil sodium’s pricing?
Pricing is influenced by formulation type, reimbursement policies, competitive landscape, and patent status. Oral formulations tend to be priced lower due to market competition.

5. What future markets or indications could expand Treprostinil sodium’s use?
Research into novel delivery routes, combination therapies, and expanded indications like chronic thromboembolic pulmonary hypertension may drive future growth.

---

Citations

1. Market research data from IQVIA 2022.
2. FDA and EMA approval archives.
3. Competitive landscape reports from Evaluate Pharma 2022.
4. Patent expiry timelines from national patent offices.
5. Clinical trial registries and recent publication data.